The Contract Network aims to solve the usually slow clinical trial agreements process with new contracting platform.
The Contract Network, a startup collaboration platform focused on accelerating contract negotiations and simplifying contract compliance, has entered into a know-how agreement with Mayo Clinic to build a solution to better manage and accelerate the negotiation of clinical trials agreements (CTA). Mayo Clinic on its website says that it conducts 12,000 clinical trials a year. With currently over 400,000 clinical trials listed on clinicaltrials.gov in the US and globally, the current negotiation processes for each of these trial agreements and related documentation are complex and time-consuming.
In a recent survey that Applied Clinical Trials* conducted, to the question “Do you consider the site agreement negotiation process a delaying factor when performing a clinical trial?”, 83% answered varying degrees of yes (sometimes 44%, most of the time 32%, all of the time. 6%). When asked of eight factors “Which factors does your company consider the top cause of study delays?” 25% said contract negotiations with clinical sites.
The Contract Network solution for CTAs is being built with sponsors, CROs, and institutions in mind, to reach agreement faster and to securely collaborate with respect to each stakeholders’ ongoing contract compliance requirements.
Jim Wagner, co-founder and CEO of The Contract Network, said in a press release, “We are incredibly proud to make clinical trial agreements the first use case for our collaborative platform and to have the opportunity to play an integral role in promoting growth and innovation in such a meaningful context." Wagner continued, "Our objective isn't just to enhance the experience for the contracting professionals involved, but also to have a positive impact on patients and the broader medical community by radically accelerating and simplifying the process of initiating new clinical trials."
The Contract Network, founded by Wagner, most recently VP of Agreement Cloud Strategy at DocuSign, and former Blackstone CTO, Bill Murphy, has been developed in stealth mode for over a year, and is set to be formally launched in May 2023.
Mayo Clinic has a financial interest in the technology referenced in the press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
*Results of the survey will be available in September 2023.
Reference: The Contract Network Collaborates with Mayo Clinic to Streamline Clinical Trials Agreements. ATLANTA, April 11, 2023 /PRNewswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.